HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bloomgarden, Z. T. Search for Related Content PubMed PubMed Citation Articles by Bloomgarden, Z. T. Social Bookmarking                What's this?

Second World Congress on the Insulin Resistance Syndrome

Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy

Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Diabetes Center, Mount Sinai School of Medicine, New York, New York

Abbreviations: ACE, American College of Endocrinology • ADMA, asymmetric dimethylarginine • ATP, Adult Treatment Panel • CRP, C-reactive protein • CVD, cardiovascular disease • DDAH, dimethylarginine dimethylaminohydrolase • DHEA, dehydroepiandrosterone • DHEAS, DHEA sulfate • FFA, free fatty acid • iCAM, intercellular adhesion molecule • IGFBP, IGF-binding protein • IGT, impaired glucose tolerance • IL, interleukin • PCOS, polycystic ovarian syndrome • PKC, protein kinase C • vCAM, vascular cell adhesion molecule • WHR, waist-to-hip ratio

The first 300 words of the full text of this article appear below.

This is the second in a series of articles on the Second World Congress on the Insulin Resistance Syndrome, Universal City, California, 18–20 November 2004.

Jacqueline Dekker (Amsterdam, the Netherlands) presented data from the Hoorn Study on the predictive power of insulin resistance syndrome diagnosis, pointing out that the public health role of identifying a person as having insulin resistance syndrome includes the ability to characterize populations to better understand the pathogenesis of adverse outcome, to allow comparison of characteristics of individuals in differing populations, and to serve a communications function in increasing risk awareness, particularly allowing identification of high-risk groups for cardiovascular disease (CVD), cancer, and diabetes. An important question is whether the existing definitions allow optimal diagnosis of high-risk groups. Comparing the Adult Treatment Panel (ATP)-III and American College of Endocrinology (ACE) definitions (1), she noted that the ACE definition starts with high-risk individuals, including non-Caucasian ethnicity, cigarette use, obesity, CVD, hypertension, polycystic ovarian syndrome (PCOS), nonalcoholic fatty liver disease, acanthosis nigricans, history of gestational diabetes or impaired glucose tolerance (IGT), and family history of type 2 diabetes, hypertension, or CVD.

The Hoorn Study included 2,484 individuals aged 50–75 in 1989–1990, with follow-up examination in 1996–1998, and population registry ascertainment of morbidity and mortality. Of 2,162 without diabetes at baseline, there were 429 deaths, 145 with malignancy and 168 with CVD. Insulin resistance syndrome components for men and women included hypertension in 68 and 66%, abdominal obesity in 16 and 40%, impaired fasting glucose in 14 and 9%, IGT in 21 and 18%, high triglycerides in 35 and 29%, and low HDL cholesterol in 28 and 35%, respectively. Twenty-one and 29% of men and women, respectively, satisfied the ATP-III definition and 46 and 42% the ACE definition of insulin resistance syndrome. Despite the greater number satisfying . . . [Full Text of this Article]

Causes and mediators of insulin resistance

Insulin resistance in children

PCOS

Insulin resistance and malignancy

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. M. Psarakis Clinical Challenges in Caring for Patients With Diabetes and Cancer Diabetes Spectr, July 1, 2006; 19(3): 157 - 162. [Abstract] [Full Text] [PDF]